New federal blood cancer program targets underserved communities
H.R. 10858 — CARE for Blood Cancer Act of 2026 · Filed by Nanette Barragán (D-CA) · 11 cosponsors · Introduced Oct 22, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill establishes a National Blood Cancer Program within the Department of Health and Human Services to coordinate federal efforts on blood cancer awareness, education, professional training, and patient support. It authorizes grants to state and local health agencies for public education and to academic institutions for research on diagnostics and treatments, with priority given to high-risk communities. The program requires annual reporting to Congress on outcomes and reach.
Why we flagged it
The bill's core mechanism is establishing a federal grant program to improve blood cancer awareness, education, and treatment access through coordination across existing agencies and funding to state/local and academic entities. This is straightforward public health infrastructure.
What the text implies
- Grant prioritization for high-risk communities may create incentive for states to develop better epidemiological data on blood cancer disparities, potentially revealing previously unmeasured health inequities.
- Academic medical center grants for treatment research may accelerate clinical trial enrollment in underserved areas, indirectly improving access to experimental therapies for patients who might otherwise lack options.
- Annual reporting requirement disaggregated by demographics and geography creates a public accountability mechanism that could expose persistent disparities and drive future policy responses.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill expands public health infrastructure and research funding for a serious disease, prioritizing underserved and high-risk populations. Citizens gain access to improved education, screening, and treatment research without any offsetting restrictions on rights or protections.
Who stands to gain
- state and local health agencies
- academic institutions and medical centers
- nonprofit health organizations
- research institutions conducting blood cancer studies
Named in the bill
Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, State health agencies, Tribal health agencies, Academic medical centers, Institutions of higher education
Where it stands
11 cosponsors: 9 Democrats, 2 Republicans.
- Oct 22, 2026 — Introduced · Congress.gov: “Introduced in House”
- Oct 22, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (5,932 characters) on Oct 23, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,417 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-24.
“New federal blood cancer program targets underserved communities” QuorumCivic. https://share.quorumcivic.app/bill/119/hr10858 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.